<p>Bicycle Therapeutics PLC 贊助的 ADR (NASDAQ:BCYC - 獲取免費報告) 週四上漲了 9.8%，因為該公司公佈的季度收益超出預期。該股最高交易價為 $8.73，最後交易價為 $8.98。在交易中，共成交 137,003 股，較平均交易量 309,305 股下降了 56%。該股此前收盤價為 $8.18。</p>
<p>該公司報告的每股收益 (EPS) 為 ($0.85)，超出市場共識預期的 ($1.05) 0.20 美元。Bicycle Therapeutics 的淨利潤率為 -1,257.00%，股本回報率為 -32.43%。</p>
<p>獲取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
<h2>分析師評級上調與下調</h2>
<p>多位股票分析師最近對 BCYC 股票發表了評論。加拿大皇家銀行在 8 月 11 日的研究報告中將 Bicycle Therapeutics 的目標價設定為 $27.00，並給予該股 &#34;跑贏大盤&#34; 的評級。JMP Securities 將 Bicycle Therapeutics 的目標價從 $22.00 下調至 $10.00，並在 8 月 12 日的報告中給予該股 &#34;市場跑贏&#34; 的評級。摩根士丹利在 8 月 12 日的報告中將 Bicycle Therapeutics 的目標價從 $17.00 下調至 $13.00，並給予該股 &#34;持平&#34; 的評級。Weiss Ratings 在 10 月 14 日的報告中重申了對 Bicycle Therapeutics 的 &#34;賣出 (d-)&#34; 評級。最後，Oppenheimer 在 8 月 11 日的研究報告中重申了 &#34;跑贏大盤&#34; 的評級，並將 Bicycle Therapeutics 的目標價下調至 $44.00（之前為 $48.00）。六位投資分析師對該股給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，共識目標價為 $22.22。</p>
<p><strong>閲讀我們對 Bicycle Therapeutics 的最新分析</strong></p>
<h2>內部人士買入與賣出</h2>
<p>在其他 Bicycle Therapeutics 的新聞中，首席執行官 Kevin Lee 於 10 月 3 日星期五出售了 3,231 股該股票。該股以平均價格 $8.41 出售，總價值為 $27,172.71。出售完成後，首席執行官持有該公司 475,310 股，價值 $3,997,357.10。這筆交易代表了他們持股比例的 0.68% 的減少。該出售在與 SEC 的法律文件中披露，文件可通過此鏈接獲取。在過去的九十天裏，內部人士共出售了價值 $71,738 的 8,527 股公司股票。公司內部人士持有公司股票的 22.90%。</p>
<h2>對 Bicycle Therapeutics 的對沖基金看法</h2>
<p>對沖基金最近買入和賣出了該公司的股票。Ausdal Financial Partners Inc. 在第二季度獲得了 Bicycle Therapeutics 的新股份，價值約 $70,000。Sei Investments Co. 在第二季度購買了 Bicycle Therapeutics 的新股份，價值 $74,000。Virtus Investment Advisers LLC 在第二季度將其在 Bicycle Therapeutics 的股份增加了 32.6%。Virtus Investment Advisers LLC 目前持有該公司 10,821 股股票，價值 $75,000，此前在上一季度又增持了 2,659 股。Ameriprise Financial Inc. 在第二季度購買了 Bicycle Therapeutics 的新頭寸，價值約 $86,000。最後，田納西州財政部在第二季度購買了 Bicycle Therapeutics 的新頭寸，價值約 $100,000。86.15% 的股票由機構投資者持有。</p>
<h2>Bicycle Therapeutics 股票上漲 9.7%</h2>
<p>該公司的市值為 $622.06 百萬，市盈率為 -2.55，貝塔係數為 1.47。該公司的 50 日移動平均線為 $7.61，200 日移動平均線為 $7.86。</p>
<h2>Bicycle Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Bicycle Therapeutics plc 是一家臨牀階段的生物製藥公司，開發一類針對美國和英國現有治療手段未能滿足的疾病的藥物。其產品管線包括 BT8009，一種正在進行 I/II/III 期臨牀試驗的自行車毒素結合物 (BTC)，用於治療高表達 nectin-4 的腫瘤；BT5528，一種正在進行 I/II 期臨牀試驗的 BTC，用於治療表達 Ephrin A 型受體 2 的腫瘤；BT7480，一種針對 Nectin-4 的自行車 TICA 分子，正在進行 I/II 期臨牀試驗，並激活 CD137；以及 BT7455，一種針對 Ephrin A 型受體 2 和 CD137 的自行車 TICA 分子，正在進行臨牀前試驗。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Bicycle Therapeutics</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>Carrier 股票在收益意外後顯得被低估</li>
<li>除了喝咖啡，還有 3 種投資咖啡的方法</li>
<li>Alphabet 第三季度業績大幅超預期，首次實現 $1000 億季度</li>
<li>技術指標如何幫助你找到被超賣的股票</li>
<li>Rocket Lab 股票下跌 14%——是否存在買入機會？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Bicycle Therapeutics 嗎？</h2>
<p>在考慮 Bicycle Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Bicycle Therapeutics 並不在名單上。</p>
<p>雖然 Bicycle Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

BCYC

<p>Bicycle Therapeutics（納斯達克代碼：BCYC）在報告季度收益好於預期後，股價上漲了 9.8%，每股收益為（$0.85），超出預期的（$1.05）。該股最高交易價達到$8.73，收盤價為$8.98。分析師的評級意見不一，普遍目標價為$22.22。首席執行官 Kevin Lee 最近出售了 3,231 股，略微減少了他的持股比例。該公司專注於開發針對未被充分滿足的疾病的藥物，市值為 6.2206 億美元，並得到了顯著的機構投資支持</p>

<p>Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) traded up 9.8% on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $8.73 and last traded at $8.98. 137,003 shares traded hands during trading, a decline of 56% from the average session volume of 309,305 shares. The stock had previously closed at $8.18.</p>
<div class="lb-trans"><p>Bicycle Therapeutics PLC 贊助的 ADR (NASDAQ:BCYC - 獲取免費報告) 週四上漲了 9.8%，因為該公司公佈的季度收益超出預期。該股最高交易價為 $8.73，最後交易價為 $8.98。在交易中，共成交 137,003 股，較平均交易量 309,305 股下降了 56%。該股此前收盤價為 $8.18。</p>
</div><p>The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.20. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%.</p>
<div class="lb-trans"><p>該公司報告的每股收益 (EPS) 為 ($0.85)，超出市場共識預期的 ($1.05) 0.20 美元。Bicycle Therapeutics 的淨利潤率為 -1,257.00%，股本回報率為 -32.43%。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of equities analysts recently commented on BCYC shares. Royal Bank Of Canada set a $27.00 price objective on shares of Bicycle Therapeutics and gave the stock an &#34;outperform&#34; rating in a research note on Monday, August 11th. JMP Securities cut their price target on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a &#34;market outperform&#34; rating on the stock in a report on Tuesday, August 12th. Morgan Stanley cut their price target on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an &#34;equal weight&#34; rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Bicycle Therapeutics in a report on Tuesday, October 14th. Finally, Oppenheimer restated an &#34;outperform&#34; rating and issued a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $22.22.</p>
<div class="lb-trans"><p>多位股票分析師最近對 BCYC 股票發表了評論。加拿大皇家銀行在 8 月 11 日的研究報告中將 Bicycle Therapeutics 的目標價設定為 $27.00，並給予該股 &#34;跑贏大盤&#34; 的評級。JMP Securities 將 Bicycle Therapeutics 的目標價從 $22.00 下調至 $10.00，並在 8 月 12 日的報告中給予該股 &#34;市場跑贏&#34; 的評級。摩根士丹利在 8 月 12 日的報告中將 Bicycle Therapeutics 的目標價從 $17.00 下調至 $13.00，並給予該股 &#34;持平&#34; 的評級。Weiss Ratings 在 10 月 14 日的報告中重申了對 Bicycle Therapeutics 的 &#34;賣出 (d-)&#34; 評級。最後，Oppenheimer 在 8 月 11 日的研究報告中重申了 &#34;跑贏大盤&#34; 的評級，並將 Bicycle Therapeutics 的目標價下調至 $44.00（之前為 $48.00）。六位投資分析師對該股給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，共識目標價為 $22.22。</p>
</div><p><strong>Read Our Latest Analysis on Bicycle Therapeutics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Bicycle Therapeutics 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買入與賣出</h2>
</div><p>In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the sale, the chief executive officer owned 475,310 shares in the company, valued at $3,997,357.10. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 8,527 shares of company stock valued at $71,738 in the last ninety days. Company insiders own 22.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Bicycle Therapeutics 的新聞中，首席執行官 Kevin Lee 於 10 月 3 日星期五出售了 3,231 股該股票。該股以平均價格 $8.41 出售，總價值為 $27,172.71。出售完成後，首席執行官持有該公司 475,310 股，價值 $3,997,357.10。這筆交易代表了他們持股比例的 0.68% 的減少。該出售在與 SEC 的法律文件中披露，文件可通過此鏈接獲取。在過去的九十天裏，內部人士共出售了價值 $71,738 的 8,527 股公司股票。公司內部人士持有公司股票的 22.90%。</p>
</div><h2>Hedge Funds Weigh In On Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>對 Bicycle Therapeutics 的對沖基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Ausdal Financial Partners Inc. acquired a new stake in Bicycle Therapeutics during the 2nd quarter worth approximately $70,000. Sei Investments Co. bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth $74,000. Virtus Investment Advisers LLC grew its stake in shares of Bicycle Therapeutics by 32.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company's stock worth $75,000 after acquiring an additional 2,659 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Bicycle Therapeutics during the second quarter valued at about $86,000. Finally, State of Tennessee Department of Treasury bought a new position in Bicycle Therapeutics during the second quarter valued at about $100,000. 86.15% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該公司的股票。Ausdal Financial Partners Inc. 在第二季度獲得了 Bicycle Therapeutics 的新股份，價值約 $70,000。Sei Investments Co. 在第二季度購買了 Bicycle Therapeutics 的新股份，價值 $74,000。Virtus Investment Advisers LLC 在第二季度將其在 Bicycle Therapeutics 的股份增加了 32.6%。Virtus Investment Advisers LLC 目前持有該公司 10,821 股股票，價值 $75,000，此前在上一季度又增持了 2,659 股。Ameriprise Financial Inc. 在第二季度購買了 Bicycle Therapeutics 的新頭寸，價值約 $86,000。最後，田納西州財政部在第二季度購買了 Bicycle Therapeutics 的新頭寸，價值約 $100,000。86.15% 的股票由機構投資者持有。</p>
</div><h2>Bicycle Therapeutics Stock Up 9.7%</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股票上漲 9.7%</h2>
</div><p>The company has a market cap of $622.06 million, a P/E ratio of -2.55 and a beta of 1.47. The company's 50-day moving average is $7.61 and its two-hundred day moving average is $7.86.</p>
<div class="lb-trans"><p>該公司的市值為 $622.06 百萬，市盈率為 -2.55，貝塔係數為 1.47。該公司的 50 日移動平均線為 $7.61，200 日移動平均線為 $7.86。</p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家臨牀階段的生物製藥公司，開發一類針對美國和英國現有治療手段未能滿足的疾病的藥物。其產品管線包括 BT8009，一種正在進行 I/II/III 期臨牀試驗的自行車毒素結合物 (BTC)，用於治療高表達 nectin-4 的腫瘤；BT5528，一種正在進行 I/II 期臨牀試驗的 BTC，用於治療表達 Ephrin A 型受體 2 的腫瘤；BT7480，一種針對 Nectin-4 的自行車 TICA 分子，正在進行 I/II 期臨牀試驗，並激活 CD137；以及 BT7455，一種針對 Ephrin A 型受體 2 和 CD137 的自行車 TICA 分子，正在進行臨牀前試驗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Carrier Stock Looks Undervalued After Earnings Surprise</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Alphabet Crushes Q3 Earnings, Reports First $100 Billion Quarter</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>Rocket Lab Stock Dips 14%—Buying Opportunity Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Bicycle Therapeutics</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>Carrier 股票在收益意外後顯得被低估</li>
<li>除了喝咖啡，還有 3 種投資咖啡的方法</li>
<li>Alphabet 第三季度業績大幅超預期，首次實現 $1000 億季度</li>
<li>技術指標如何幫助你找到被超賣的股票</li>
<li>Rocket Lab 股票下跌 14%——是否存在買入機會？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Bicycle Therapeutics 嗎？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Bicycle Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Bicycle Therapeutics 並不在名單上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bicycle Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bicycle Therapeutics（NASDAQ:BCYC）股價因業績超預期上漲 9.8%